TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and JOHN GLENNTender Agreement • December 23rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 23rd, 2013 Company Industry JurisdictionThis TENDER AGREEMENT, dated as of December 15, 2013 (this “Agreement”), is among Valeant Pharmaceuticals International, a Delaware corporation (“Parent”), Sapphire Subsidiary Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and John Glenn (“Company Stockholder”).
TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and INLIGN CP III, LLCTender Agreement • December 23rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 23rd, 2013 Company Industry JurisdictionThis TENDER AGREEMENT, dated as of December 15, 2013 (this “Agreement”), is among Valeant Pharmaceuticals International, a Delaware corporation (“Parent”), Sapphire Subsidiary Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and Inlign CP III, LLC, a Delaware limited liability company (“Company Stockholder”).
TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and DAVID HOLTHETender Agreement • December 23rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 23rd, 2013 Company Industry JurisdictionThis TENDER AGREEMENT, dated as of December 15, 2013 (this “Agreement”), is among Valeant Pharmaceuticals International, a Delaware corporation (“Parent”), Sapphire Subsidiary Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and David Holthe (“Company Stockholder”).
TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and JEFF NARDOCITender Agreement • December 23rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 23rd, 2013 Company Industry JurisdictionThis TENDER AGREEMENT, dated as of December 15, 2013 (this “Agreement”), is among Valeant Pharmaceuticals International, a Delaware corporation (“Parent”), Sapphire Subsidiary Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and Jeff Nardoci (“Company Stockholder”).
TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and ERIC STANGTender Agreement • December 23rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 23rd, 2013 Company Industry JurisdictionThis TENDER AGREEMENT, dated as of December 15, 2013 (this “Agreement”), is among Valeant Pharmaceuticals International, a Delaware corporation (“Parent”), Sapphire Subsidiary Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and Eric Stang (“Company Stockholder”).
TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and HAROLD L. COVERTTender Agreement • December 23rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 23rd, 2013 Company Industry JurisdictionThis TENDER AGREEMENT, dated as of December 15, 2013 (this “Agreement”), is among Valeant Pharmaceuticals International, a Delaware corporation (“Parent”), Sapphire Subsidiary Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and Harold L. Covert (“Company Stockholder”).
TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and CATHY L. MCCARTHYTender Agreement • December 23rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 23rd, 2013 Company Industry JurisdictionThis TENDER AGREEMENT, dated as of December 15, 2013 (this “Agreement”), is among Valeant Pharmaceuticals International, a Delaware corporation (“Parent”), Sapphire Subsidiary Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and Cathy L. McCarthy (“Company Stockholder”).
TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and LINDA GRAEBNERTender Agreement • December 23rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 23rd, 2013 Company Industry JurisdictionThis TENDER AGREEMENT, dated as of December 15, 2013 (this “Agreement”), is among Valeant Pharmaceuticals International, a Delaware corporation (“Parent”), Sapphire Subsidiary Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and Linda Graebner (“Company Stockholder”).
TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and MARK M. SIECZKAREKTender Agreement • December 23rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 23rd, 2013 Company Industry JurisdictionThis TENDER AGREEMENT, dated as of December 15, 2013 (this “Agreement”), is among Valeant Pharmaceuticals International, a Delaware corporation (“Parent”), Sapphire Subsidiary Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and Mark M. Sieczkarek (“Company Stockholder”).
TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and H. DANIEL FERRARITender Agreement • December 23rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 23rd, 2013 Company Industry JurisdictionThis TENDER AGREEMENT, dated as of December 15, 2013 (this “Agreement”), is among Valeant Pharmaceuticals International, a Delaware corporation (“Parent”), Sapphire Subsidiary Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and H. Daniel Ferrari (“Company Stockholder”).